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This study compares the sensitivities and specificities of three techniques for the detection of circulating epithelial cells in the blood of
patients with breast cancer. The number of circulating epithelial cells present in the blood of 40 patients with metastatic breast cancer
and 20 healthy volunteers was determined by: immunomagnetic separation (IMS) and laser scanning cytometry (LSC), cell filtration
and LSC and a multimarker real-time RT–PCR assay. Numbers of cytokeratin-positive cells identified and expression of three PCR
markers were significantly higher in the blood of patients with breast cancer than in healthy volunteers. Using the upper 95%
confidence interval of cells detected in controls to determine positive patient samples: 30% of patients with metastatic breast cancer
were positive following cell filtration, 48% following IMS, and 60, 45 and 35% using real-time RT–PCR for cytokeratin 19,
mammaglobin and prolactin-inducible peptide. Samples were significantly more likely to be positive for at least one PCR marker than
by cell filtration (83 vs 30%, Po0.001) or IMS (83 vs 48%, Po0.001).The use of a multimarker real-time RT–PCR assay was therefore
found to be the most sensitive technique for the detection of circulating epithelial cells in the blood of patients with breast cancer.
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Over recent years, it has become apparent that circulating
epithelial cells, assumed to represent metastatic tumour cells, can
be detected in the blood of many patients with breast cancer (Ring
et al, 2004). The detection of such cells could have significant
clinical utility in risk stratification in early breast cancer, in early
detection of relapse and in monitoring response to treatment.
Cytometric techniques based on immunohistochemical analyses
and nucleic acid-based approaches to cell detection have been
described (Racila et al, 1998; Lambrechts et al, 1999; Smith et al,
2000; Aerts et al, 2001; Stathopoulou et al, 2002; Witzig et al, 2002).
However, there is considerable variability in the reported
sensitivities and specificities of existing techniques with putative
carcinoma cells reported to be present in between 0 and 100% of
blood samples from patients with metastatic breast cancer (Ring
et al, 2004). Unfortunately, the design of published studies makes
it difficult to compare directly the performance of current
techniques and therefore to ascertain the optimal approach.
In the current study, we directly compare three techniques for
the detection of circulating epithelial cells in the blood of patients
with breast cancer and a healthy volunteer control population. The
first technique combines positive immunomagnetic separation
(IMS) with laser scanning cytometry (LSC), techniques that have
both previously been applied to circulating epithelial cell detection
(Brandt et al, 1998; Pachmann et al, 2001; Witzig et al, 2002). The
second technique uses a novel approach to enrichment based on
cell filtration as described by Vona et al (2000), and previously
used in our own studies in combination with LSC (Zabaglo et al,
2003). The final method of analysis is a multiple marker real-time
RT–PCR assay. The PCR assay was developed to detect cytokeratin
19 (CK19), mammaglobin and prolactin-inducible peptide (PIP)
(Clark et al, 1999), which are expressed in breast epithelial cells but
at low levels in normal blood components. CK19 was chosen as it is
expressed in the majority of breast cancers (Bartek et al, 1986;
Moll, 1994), and has been extensively used in studies in this area
(Slade et al, 1999; Smith et al, 2000; Aerts et al, 2001; Stathopoulou
et al, 2002, 2003). Mammaglobin gene expression has previously
been used to detect circulating breast cancer micrometastases with
no false positives in control populations (Zach et al, 1999; Silva
et al, 2002). In a recent study, mammaglobins, and the third
marker PIP, were found to be the most sensitive and specific
markers for the detection of micrometastatic breast cancer in
axillary lymph nodes (Mitas et al, 2003).
MATERIALS AND METHODS
Clinical samples
Ethical approval was granted for this study by the Royal Marsden
Hospital Local Research and Ethics Committee, and written
informed consent was obtained. Patients were eligible if they had
metastatic breast cancer (stage IV according to AJCC criteria
(Singletary et al, 2002)) and were not receiving cytotoxic
chemotherapy at the time of enrolment (endocrine and bispho-
sphonate therapy were permitted). Healthy volunteers were
selected from the staff of the Academic Department of Biochem-
istry and the Royal Marsden Hospital Breast Unit. One 18ml blood
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ssample was taken from each subject via a peripheral vein.
Venepuncture was with a 21- or 23-G needle, and the first 5ml
were discarded to minimise contamination by skin epithelial cells.
Samples were taken into EDTA tubes (Greiner Bio-One Ltd,
Stonehouse, UK) and processed within 30min of venesection.
All analyses were conducted blind of the patient/control status
of the samples.
Each sample was split into 6ml aliquots for analysis by one of
the following three techniques:
IMS followed by LSC: The 6ml blood sample was subjected to
density gradient enrichment over an equal volume of Histopaque-
1077 (Sigma-Aldrich Company Ltd, Poole, UK). The protocol used
and PBS washes were according to the manufacturer’s instructions.
The resulting cell pellet was resuspended in 100ml of PBS and
incubated with mouse BerEP4-FITC (20mgml
 1) antibody (Dako,
Cambridge, UK) for 10–15min at room temperature. Two washes
were performed in IMS buffer (Ca
2þ- and Mg
2þ-free PBS, 0.5%
bovine serum albumin and 2mM EDTA) prior to incubation with
goat anti-mouse IgG Microbeads (Miltenyi-Biotec Ltd, Surrey, UK)
for 15min at 41C. After further washes in buffer, the cells were
subjected to magnetic separation using a MiniMACS separation
column (Miltenyi-Biotec Ltd, Surrey, UK). The positive fraction
was centrifuged and resuspended in PBS and a cytospin prepared
using a Hettich Universal 32R centrifuge (Hettich-Zentrifugen,
Germany). The cytospin spot deposited on a microscope slide was
fixed in 100% methanol for 10min and air-dried.
For cytokeratin staining slides were rehydrated in PBS followed
by TBP (0.5% Triton X-100 and 0.5% bovine serum albumin in
PBS) and blocked with normal rabbit serum. Slides were then
incubated for 1h in a 1:10 dilution of anti-pan-cytokeratin (5/6/8/
17/19)-FITC (MNF116, Dako, Cambridge, UK) in TBP. The nuclei
were then counterstained with 20mgml
 1 propidium iodide (PI;
Sigma-Aldrich Company Ltd, Poole, UK) and 100mgml
 1 RNase
(Sigma-Aldrich Company Ltd, Poole, UK) for 30min. Slides were
mounted in Vectashield containing 5mgml
 1 PI (Vector Labora-
tories Ltd, Peterborough, UK). The MCF7 breast cancer cell line
was used as a positive control, and an isotype mouse IgG1
antibody as a negative control.
Slides were analysed using a Laser Scanning Cytometer
(CompuCyte Inc., Cambridge, MA, USA) with WinCyte PC-based
software as we have described previously (Zabaglo et al, 2003).
Briefly, the slides were scanned using the argon laser 488-nm line,
and the cells separated on the basis of the DNA fluorescence area,
maximal pixel intensity, integrated fluorescence and perimeter
into cell clumps, doublets and single cells. Green fluorescence
(FITC-labelled cytokeratin) against integrated red fluorescence was
displayed for each of the three cell populations and cytokeratin-
positive cells identified. After analysis, all the cytokeratin-positive
cells were relocated and examined by eye; only cells fulfilling the
criteria of the European ISHAGE Working Group (European
ISHAGE Working Group, 1999) were accepted as positive.
Cell filtration followed by LSC: Blood samples, diluted 1:1
in PBS 2mM EDTA, were filtered under gravity through a
Poretics polycarbonate Track-Etch-type (PCTE) membrane
(Genetic Research Instrumentation Ltd, Braintree, UK)
with calibrated 8mm cylindrical pores, as described previously
(Zabaglo et al, 2003). The filters were then washed with PBS and
fixed in 100% methanol prior to being removed from their holders
and attached to a microscope slide. Slides were stained for
cytokeratin and LSC analysis performed as for samples prepared
by IMS.
Real-time RT–PCR: Samples were subjected to density grad-
ient enrichment using Histopaque-1077 (Sigma-Aldrich Company
Ltd, Poole, UK) as described for IMS. The cell pellets were
stored in liquid nitrogen, and RNA extraction performed
using TRIzol Reagent (Invitrogen Ltd, Paisley, UK) and RNA
quantification using an Agilent 2100 Bioanalyser (Agilent Tech-
nologies Ltd, West Lothian, UK). DNase treatment was carried out
using an RQ1 RNase-free DNase kit (Promega, Southampton,
UK), according to the manufacturer’s instructions. The RNA
pellets were dissolved in nuclease-free water and stored at  701C
prior to use.
Primers and probes were designed for CK19, mammaglobin, PIP
and the ribosomal RNA RPL19 using Primer Expresst software
(Applied Biosystems, Warrington, UK). Where possible, primers
and probes were designed to span intron–exon junctions, and in
the case of CK19 to capitalise on sequences of nonhomology
between CK19 cDNA and its known pseudogenes (Ruud et al,
1999). BLAST sequence similarity searches (www.ncbi.nlm.nih.
gov/BLAST) were performed to confirm that there was no
significant homology between the sequences chosen and other
genes in the database. The final sequences and labels used are
shown in Table 1. The oligonucleotides were synthesised by
Applied Biosystems (Warrington, UK).
Reverse transcription and real-time RT–PCR was carried out
using the ABI Prism 7900HT operating system (Applied Biosys-
tems, Warrington, UK). For each test gene, 10ml of DNase-treated
RNA (20ngml
 1) was added to 50mlo f2 AmpliTaq Gold
s DNA
polymerase master mix, 2.5ml4 0  Multiscribet reverse tran-
scriptase (both Applied Biosystems, Warrington, UK), forward and
reverse primers and probe at the optimised concentrations, and
nuclease-free water to a total volume of 100ml. A measure of 25ml
of this mix was added to three wells such that each sample was run
in triplicate with 50ng of RNA template. All sample plates were run
with positive controls (T47D breast cancer cell line RNA) and no-
template negative controls. The following thermal cycling condi-
tions were used: 481C for 30min; 951C for 10min; 40 cycles of 951C
for 15s followed by 601C for 60s.
Mean threshold (Ct) values, the number of cycles after which the
emitted fluorescence crossed the threshold fluorescence, were
calculated for each sample for each of the test genes and the RPL19
normaliser. These were converted to mean normalised gene
Table 1 Primer and probe sequences for the target genes
Target gene
Gene bank
accession
number
Forward primer
sequence
Reverse primer
sequence
Probe
sequence
50
label
30
quencher
CK19 NM002276 TGCGGGACAAGATTCTTGGT TCTCAAACTTGGTTCGGAAGTCA ACCATTGAGAACTCCAGGATTG
TCCTGCA
6-FAM TAMRA
Mammaglobin AF015224 TGCCATAGATGAATTGA
AGGAATG
TCATATATTAATTGCATAAACA
CCTCAACA
ACCAAACGGATGAAACT 6-FAM MGB
PIP J03460 TGGAAGCCCTGTCTGTTTGC AGCAGAAATTCCAGCCAAGTTTC CCCAGGTGATTTCC 6-FAM MGB
RPL19 NM000981 CCATGAGTATGCTCAGGCTTCA CTGACGGGAGTTGGCATTG CCTCTAGTGTCCTCCGC
TGTGGCAAG
VICt TAMRA
CK19¼cytokeratin 19; PIP¼prolactin-inducible peptide; 6-FAM, 6-carboxyfluorescein; TAMRA, 6-carboxytetramethylrhodamine; MGB, minor groove binder, nonfluorescent
quencher.
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sexpression (MNE) using the following equation (Muller et al,
2002):
MNE ¼
ðErefÞ
Ct ref mean
ðEtargetÞ
Ct targetmean
where MNE is the mean normalised expression, Eref is the PCR
amplification efficiency of the reference gene, Etarget is the PCR
amplification efficiency of the target gene, Ct ref is the threshold
cycle of the PCR amplification of the reference gene and Ct target is
the threshold cycle of PCR amplification of the target gene. When
the PCR amplification curve had not passed the threshold
fluorescence after 40 cycles, the marker was described as
undetectable in that sample and the MNE designated zero.
Statistics
Differences between the number of circulating cell numbers
between the control and patient populations were assessed using
the Mann–Whitney U-test for unpaired non-normally distributed
groups. Differences in cell numbers between the two cytometric
techniques were analysed with the Wilcoxon signed-rank test for
paired non-normally distributed groups. Correlations between the
three techniques were assessed by calculating Spearman’s rank
correlation coefficient. Differences in positivity rates between the
three techniques were assessed using the McNemar test. The w
2 test
was used to assess the relation between patient characteristics and
rates of positive samples. Values of Po0.05 were considered
statistically significant. StatView 4.5 software (Cherwell Scientific,
UK) was used throughout.
RESULTS
Baseline characteristics
Blood samples were taken from 40 patients with metastatic breast
cancer and from 20 healthy volunteers. All analyses were
performed blinded to the patient/control status of samples. The
patients’ baseline characteristics are shown in Table 2.
Detection by LSC following IMS
In the 20 control subjects, the mean number of positive epithelial
cells detected was 0.406ml
 1 using LSC following IMS. In the 40
patients with metastatic breast cancer, the mean number of
positive cells detected was 6.556ml
 1 (Po0.001, Mann–Whitney
U-test). Positive cells were identified in the blood of four out of 20
(20%) healthy volunteers compared with 34 out of 40 (85%)
patients with metastatic breast cancer (Figure 1). In common with
a previous study, the upper 95% confidence interval of mean cell
numbers in controls was used as a cutoff to define positive samples
in patients with metastatic breast cancer (Aerts et al, 2001). Using
such a threshold, 19 out of 40 (48%) samples from patients with
metastatic breast cancer were positive. An alternative way to
analyse this data is to set a threshold value for positive samples in
the patient population, which corresponds to 100% specificity in
the control population. Using this approach 15 out of 40 (38%)
samples from patients with metastatic breast cancer were positive.
Detection by LSC following cell filtration
In the 20 control subjects, the mean number of positive epithelial
cells detected was 0.426ml
 1 blood sample using LSC following
cell filtration. In the 40 patients with metastatic breast cancer, the
mean number of positive cells detected was 3.876ml
 1 (P¼0.0012,
Mann–Whitney U-test). Positive cells were identified in the blood
of five out of 20 (25%) healthy volunteers compared with 28 out of
40 (70%) patients with metastatic breast cancer (Figure 2). Using
the upper 95% confidence interval of mean cell numbers in
controls as a cutoff, 12 out of 40 (30%) samples from patients with
metastatic breast cancer were positive. Alternatively ensuring
100% specificity in the control population, 10 out of 40 (25%)
samples from patients with metastatic breast cancer were positive.
Table 2 Baseline characteristics of the 40 patients with metastatic breast
cancer enrolled in the study
Characteristic
Patients with stage IV
breast cancer (n¼40)
Median age (years) (range) 56.5 (24–77)
Sites of metastatic disease
Bone 23 (58%)
Lymph node 22 (55%)
Liver 24 (60%)
Lung/pleural 21 (53%)
Skin 5 (13%)
Number of sites of disease
1 7 (18%)
2 17 (43%)
42 16 (40%)
Current therapy
Endocrine 22 (55%)
Chemotherapy 0
None 18 (45%)
Number of previous chemotherapy regimens
0 5 (13%)
1 19 (48%)
2 10 (25%)
42 6 (15%)
Number of previous endocrine regimens
0 7 (18%)
1 14 (35%)
2 12 (30%)
42 7 (18%)
Previous radiation therapy for metastatic disease 16 (40%)
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Figure 1 Number of positive epithelial cells detected per 6ml blood
sample in breast cancer patients and healthy volunteers when blood
samples were analysed by LSC following IMS.
Circulating tumour cells in breast cancer
AE Ring et al
908
British Journal of Cancer (2005) 92(5), 906–912 & 2005 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sDetection by real-time RT–PCR for CK19, mammaglobin
and PIP
The MNE values for the patients and healthy volunteer controls for
the three PCR targets are shown in Table 3. Differences in MNE
between the healthy volunteers and patients were statistically
significant for all three markers: CK19 (Po0.0001), mammaglobin
(P¼0.0011) and PIP (P¼0.002). There were no statistically
significant differences between the Ct values for RPL19 for the
patients and controls (22.53 vs 22.47, P¼0.58). The MNE for
individual subjects for each of the three markers are shown in
Figures 3–5.
The upper 95% confidence interval of MNE in control subjects
was used as a cutoff to define positive samples in patients with
metastatic breast cancer. Using this threshold, 24 out of 40 (60%)
samples from patients with metastatic breast cancer were positive
for CK19, 18 out of 40 (45%) were positive for mammaglobin and
14 out of 40 (35%) were positive for PIP. Using a threshold to
ensure 100% specificity in the control population 22 out of 40
(55%) samples from patients with metastatic breast cancer were
positive for CK19 compared with 18 out of 40 (45%) for
mammaglobin and seven out of 40 (18%) for PIP.
Regarding all 40 blood samples from the patients and using the
95% confidence interval threshold: seven (18%) were negative for
all of the genes, 16 (39%) positive for only one gene, 11 (28%)
positive for two genes and six (15%) positive for all three genes. In
the 20 healthy volunteers: two (10%) were positive for one gene,
but none of them was positive for more than one gene (Table 4).
Using a threshold to ensure 100% specificity in the control
population, 11 (28%) of patient samples were negative for all of the
genes, 15 (38%) positive for only one gene, 10 (25%) positive for
two genes and four (10%) positive for all three genes (Table 4).
There were no significant differences between the number of
samples positive for CK19 and mammaglobin, and PIP and
mammaglobin. However, significantly more samples from patients
with metastatic breast cancer were positive for CK19 than for PIP
(60 vs 35%, P¼0.014). Concordant samples were defined as those
where the patient sample was reported as either positive or
negative by both of the markers being used. As such, the
concordance between CK19 and mammaglobin was 65%, between
CK19 and PIP was 53%, and between PIP and mammaglobin was
50%.
Comparisons between the three techniques
The differences in mean cell numbers detected by LSC following
IMS and cell filtration in patients with metastatic breast cancer did
not reach statistical significance (Wilcoxon’s signed rank test,
P¼0.08). There was also no significant difference between the
number of samples defined as positive by LSC following IMS and
6
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Figure 2 Number of positive epithelial cells detected per 6ml blood
sample in breast cancer patients and healthy volunteers when blood
samples were analysed by LSC following cell filtration enrichment.
Table 3 MNE of CK19, mammaglobin and PIP assessed in the blood of 40 patients with metastatic breast cancer and 20 healthy volunteers by real-time
RT–PCR
Test gene
MNE healthy
volunteers (n¼20)
(range)
Healthy volunteers
in whom test gene
detectable (n¼20)
MNE patients with
metastatic breast
cancer (n¼40) (range)
Patients in whom test
gene detectable (n¼40)
CK19 0.0000996 (0–0.00049) 7 (35%) 0.001780 (0–0.032) 37 (93%)
Mammaglobin 0.0000013 (0.000025) 1 (5%) 0.000578 (0–0.01870) 18 (45%)
PIP 0.000043 (0–0.000241) 13 (65%) 0.000128 (0.000014-0.000543) 40 (100%)
MNE¼mean normalised expression; CK19¼cytokeratin 19; PIP¼prolactin-inducible peptide; RT–PCR¼reverse transcriptase–polymerase chain reaction.
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Figure 3 Mean normalised expression of CK19 detected in blood
samples from patients with metastatic breast cancer and healthy volunteers
when samples were analysed by real-time RT–PCR (CK19, cytokeratin 19).
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scell filtration (48 vs 30%, P¼0.18, McNemar test). There were
significant correlations between the numbers of cells detected by
LSC following cell filtration and IMS both in patients with
metastatic breast cancer and in controls (Spearman’s rank
correlation coefficient, r¼0.432, P¼0.007 and r¼0.742,
P¼0.0012, respectively).
Using the 95% confidence interval threshold in controls to
define positive samples, patients with metastatic breast cancer
were significantly more likely to be positive using the real-time
RT–PCR assay for CK19 than using cell filtration followed by LSC
(60 vs 30%, P¼0.006, McNemar test), but this was not the case
comparing the CK19 RT–PCR assay with IMS followed by LSC (60
vs 48%, P¼0.06). However, when all three PCR markers were used,
samples from patients with metastatic breast cancer were
significantly more likely to be positive for at least one of the
markers than they were likely to be positive by cell filtration or
IMS followed by LSC (83 vs 30%, Po0.001 and 83 vs 48%,
Po0.001, respectively).
Using the threshold set at 100% specificity, samples from
patients with metastatic breast cancer were also significantly more
likely to be positive for at least one of the markers than to be
positive by cell filtration or IMS followed by LSC (73 vs 25%,
Po0.001 and 73 vs 38%, Po0.01, respectively).
Concordant samples were defined as those where the sample
from a patient was reported as either positive or negative by both
of the techniques being compared. As a result, the concordance
between samples analysed by cell filtration and IMS was 65%. Of
the 12 patients positive by cell filtration, nine were also positive by
IMS. When IMS and real-time RT–PCR for CK19, mammaglobin
and PIP were compared, the concordances were 65, 70 and 50%,
respectively. The corresponding figures for cell filtration compared
with the real-time RT–PCR assays were: 60, 60 and 50%.
The concordance between samples defined as positive as a result
of expressing all three test genes and those defined as positive by
cell filtration and IMS was 73 and 60%, respectively.
DISCUSSION
The detection of circulating tumour cells has considerable
potential to influence the management of patients with breast
cancer. However, using existing techniques there is considerable
variability in the rates of positive samples in patients with
Breast cancer patients    Healthy volunteers 
M
e
a
n
 
n
o
r
m
a
l
i
s
e
d
 
e
x
p
r
e
s
s
i
o
n
 
o
f
 
m
a
m
m
a
g
l
o
b
i
n
 
0.0187 
0.001 
0.0005 
0 
Figure 4 Mean normalised expression of mammaglobin detected in
blood samples from patients with metastatic breast cancer and healthy
volunteers when samples were analysed by real-time RT–PCR.
Breast cancer patients    Healthy volunteers 
M
e
a
n
 
n
o
r
m
a
l
i
s
e
d
 
e
x
p
r
e
s
s
i
o
n
 
o
f
 
P
I
P
 
0 
0.0001 
0.0002 
0.0003 
0.0004 
0.0005 
0.0006 
Figure 5 Mean normalised expression of PIP detected in blood samples
from patients with metastatic breast cancer and healthy volunteers when
samples were analysed by real time RT-PCR. (PIP, prolactin-inducible
peptide).
Table 4 Number of healthy volunteers and patients positive for none, at least one or all three of the test genes (CK19, mammaglobin and PIP) by real-
time RT–PCR
Healthy volunteers (n¼20) Patients (n¼40)
Level of specificity Level of Specificity
Number of genes positive 95% 100% 95% 100%
None 18 (90%) 20 (100%) 7 (18%) 11 (28%)
X1 2 (10%) 0 (0%) 33 (83%) 29 (73%)
All 3 0 (0%) 0 (0%) 6 (15%) 4 (10%)
CK19¼cytokeratin 19; PIP¼prolactin-inducible peptide; RT–PCR¼reverse transcriptase–polymerase chain reaction. Positive samples defined using either the upper 95%
confidence interval of levels in the healthy volunteers to describe positive samples or using a threshold that provided 100% specificity in healthy volunteers.
Circulating tumour cells in breast cancer
AE Ring et al
910
British Journal of Cancer (2005) 92(5), 906–912 & 2005 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
smetastatic breast cancer and in control populations. Therefore, it is
important to compare directly techniques, in order to ascertain the
optimal approaches to use.
Using LSC following IMS and cell filtration more circulating
epithelial cells were detected in the blood of patients with
metastatic breast cancer than in control healthy volunteers.
Similarly, the expression of CK19, mammaglobin and PIP was
found to be significantly higher in the blood of patients with
metastatic breast cancer than in controls. A cutoff for positivity
was defined for all three techniques based on the upper 95%
confidence intervals of mean cell numbers in the control
population. On this basis, 30% of the patient samples were
positive by filtration, 48% by IMS enrichment and 35–60% using
real-time RT–PCR depending on the test gene used. The rates of
positive samples using the cytometric techniques and real-time
RT–PCR are within the previously observed ranges using such
techniques to detect circulating epithelial cells in the blood of
patients with metastatic breast cancer (Smith et al, 2000; Bosma
et al, 2002; Baker et al, 2003; Stathopoulou et al, 2003; Ring et al,
2004).
This study demonstrates the benefit of using more than
one target for RT–PCR amplification. If using CK19, mammaglo-
bin or PIP alone, then 60, 45 and 35% of samples would be
expected to be positive. However, 82% of patients were positive for
at least one of these markers. The relatively low concordance
values for positivity between the different markers (50–65%)
probably reflects not only differences in sensitivity but also that
the different markers are identifying different populations of cells:
in fact, of the 16 CK19-negative patients, five were PIP positive.
This reinforces the benefit of using a multiple marker PCR assay.
Similar results were reported by Taback and colleagues who used
RT–PCR to assess the expression of four genes in the blood of 65
patients with breast cancer (stage I–IV) and 40 normal volunteers
(Taback et al, 2001). Individual markers were detected in 11–37%
of patients, but at least one marker was detected in the blood of
69% of patients. These two studies demonstrate that although no
one marker may be ideal for the detection of circulating tumour
cells, the use of a multiple marker assay may significantly improve
sensitivity.
In a further study published by Baker et al, 13 out of 20
(65%) patients with metastatic breast cancer had overexpression
in their blood of at least one of six test genes (Baker et al, 2003).
This study also provides evidence that enrichment using
porous barrier density gradient centrifugation reduces back-
ground expression of CK19 and MUC1 compared with a Ficoll
density gradient similar to that used in the current study.
Therefore, it may prove to be possible to further improve on the
real-time RT–PCR results reported here by modifying the
enrichment step.
As far as comparisons between the techniques are concerned,
the CK19 RT–PCR assay was found to be more sensitive than cell
filtration followed by LSC, although there was no significant
difference compared with IMS followed by LSC. However, when all
three markers are taken into consideration, samples from patients
with breast cancer are more likely to have a positive result with at
least one of the markers than either of the two cytometric
techniques (both Po0.001). These results show that when a
multiple marker real-time RT–PCR assay is used, its sensitivity
exceeds that of both an established and a novel cytometric
technique. Previous studies using nonquantitative RT–PCR also
reveal more positive results when patient samples are analysed by
PCR than by immunocytochemical techniques (Schoenfeld et al,
1997; Lambrechts et al, 1999). However, these results may be
compromised by lower specificity (Lambrechts et al, 1999). Slade
and colleagues used a competitive PCR reaction to enable relative
quantification of samples and to establish a cutoff point for
positivity based on analyses of the blood of normal individuals
(Slade et al, 1999). Using such an approach for CK19, it was found
that 50% of samples from patients with metastatic breast cancer
were positive by PCR compared with 42% of samples analysed
using immunocytochemistry (Smith et al, 2000).
Aside from the relative sensitivities and specificities of
the different techniques, the correlations between the techniques
and their concordance are also of interest. Good correlations
were observed between cell numbers detected by the two
cytometric techniques and between real-time RT–PCR for CK19
and IMS enrichment. However, when a cutoff for positivity is
established, the concordance between techniques was between 68
and 75%, meaning that although the sensitivity of techniques may
be similar, the samples being called positive and negative are not
necessarily the same. Other studies show qualitative concordance
between PCR-based assays and immunocytochemistry of 71–77%
(Schoenfeld et al, 1997; Smith et al, 2000). In the case of the
cytometric techniques, the limited concordance may reflect the
differences in specimen handling. The differences between the
real-time RT–PCR technique and the cytometric techniques may
be further explained by the different markers detected and the
determination of expression at an RNA as opposed to a protein
level. An important corollary of this observation is that
cytokeratin-positive cells identified by one technique should not
be assumed to have the same significance as those detected by
another technique: the populations of cells detected may be
distinct and have different clinical, biological and prognostic
significance.
The quantitative nature of the real-time RT–PCR assay makes it
an ideal technique by which to establish a normal range of
expression for markers in controls. This was a comparative study
and hence the same approach was used in the cytometric
techniques. Such an approach predetermines the specificity of
the assay. In order to assess fully the sensitivity and specificity of
these techniques, the cohort presented in this study should be
regarded as a training set. The established cutoffs for positivity
should now be used in an independent validation set, to establish
fully the clinical performance of the technique. A second issue
when considering RNA-based assays such as RT–PCR is that RNA
is inherently labile and therefore blood should be analysed as soon
as possible after sampling. This may not be practical if samples (as
seems likely) need to be transferred to a central laboratory for
analysis. This practical issue may limit the widespread clinical
utility of the PCR approach, although recently blood RNA tubes
have become available (PAXgenet, Qiagen Ltd, Crawley, UK),
which may be able to overcome this problem.
These caveats aside, these data show that using a real-time RT–
PCR assay there is evidence of circulating tumour cell dissemina-
tion in the blood of up to 80% of patients with metastatic breast
cancer. Although such analysis of blood samples may enable the
monitoring of responses to treatment, in the absence of further
characterisation of the significance of the cells, the clinical utility
of the approach may be limited. The ascertainment of circulating
individual cell phenotype at relapse and during therapy could
significantly enhance our understanding of mechanisms of
resistance and facilitate targeting of therapy, but is only likely to
be possible using cytometric techniques. Circulating tumour cell
detection theoretically would have its greatest impact in the
management of early breast cancer, where risk stratification may
be improved and responses to adjuvant therapy and the detection
of relapse monitored. However, not all patients even with
metastatic disease have detectable circulating tumour cells, so
whether a significant role will emerge will depend on applying such
techniques in large prospective studies in patients with early breast
cancer.
In summary, the data presented suggest that the use of a
multiple marker real-time RT–PCR assay may be a more sensitive
technique by which to detect circulating breast cancer cells than
the use of a novel or an established cytometric technique. This
does not necessarily mean that the PCR-based assay is superior to
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the different approaches. If the aim of the technique is to assess
blood ‘tumour burden’, such as if one is monitoring responses to
treatment, then real-time RT–PCR may be the superior approach.
However, if it is desirable to visualise cells directly and perhaps
perform further phenotypic or molecular characterisation, then a
cytometric approach may be preferable.
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